Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...

There has been considerable controversy surrounding Aduhelm since the Food and Drug Administration (FDA) granted the drug accelerated approval in 2021. The accelerated approval of Aduhelm has been ...

(Reuters) -Biogen will end a post-approval study of Alzheimer's treatment Aduhelm and return the licensing rights on the drug after failing to find a partner to mitigate costs of obtaining standard ...

Biogen said it will discontinue the development and commercialization of its older and highly controversial Alzheimer's drug Aduhelm to refocus its efforts to treat the memory-robbing disease. The ...

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history ...

Biogen will stop developing its Alzheimer's treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that ...

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that ...

Aduhelm’s annual list price would be cost-effective at $3,000 to $8,400, a range representing a 85-95 percent discount from its current $56,000 annual price, the Institute for Clinical and Economic ...

Aduhelm (aducanumab-avwa) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid solution for intravenous (IV) infusion by a healthcare professional. It’s usually ...